Breast cancer drug approved after UK pharma deal with Trump

A previously rejected breast cancer drug, initially turned down by English health watchdogs due to cost concerns, has been approved following a significant pharmaceutical deal between the UK and the Trump administration. This decision will make the treatment accessible to around 1,000 women annually. The approval is notable as it marks a shift in policy, potentially impacting patient access and healthcare discussions around cost-effectiveness and international relations in medical approvals. For more details, check out the full article on Financial Times.